Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cytodyn Inc (CYDY)

Cytodyn Inc (CYDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cytodyn Inc 1111 MAIN STREET SUITE 660 VANCOUVER WA 98660 USA

www.cytodyn.com P: 360-980-8524

Description:

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.

Key Statistics

Overview:

Market Capitalization, $K 133,272
Enterprise Value, $K 124,932
Shares Outstanding, K 993,826
Annual Sales, $ 0 K
Annual Net Income, $ -79,820 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -11,920 K
EBIT, $ -15,170 K
EBITDA, $ -3,120 K
60-Month Beta 0.21
% of Insider Shareholders 0.71%
% of Institutional Shareholders 5.06%
Float, K 986,770
% Float 99.29%
Short Volume Ratio 0.51

Growth:

1-Year Return -48.02%
3-Year Return -92.90%
5-Year Return -73.18%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 65.52%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.01 on 04/15/24
Next Earnings Date N/A
Earnings Per Share ttm -0.05
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 50.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CYDY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -478.47%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.12
Interest Coverage -2.17
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar